This Article Full Text Full Text (PDF) All Versions of this Article: 90/6/3168    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bechtold, S. Articles by Schwarz, H. P. Search for Related Content PubMed PubMed Citation Articles by Bechtold, S. Articles by Schwarz, H. P. Related Collections Pediatric Endocrinology Calcium and Bone Metabolism

Growth Hormone Changes Bone Geometry and Body Composition in Patients with Juvenile Idiopathic Arthritis Requiring Glucocorticoid Treatment: A Controlled Study Using Peripheral Quantitative Computed Tomography

Division of Pediatric Endocrinology, University Children’s Hospital (S.B., W.B., R.D.P., H.P.S.), Munich, Germany; and Children’s Rheumatology Clinic (P.R., R.H.), Garmisch-Partenkirchen, Germany

Address all correspondence and requests for reprints to: Dr. Susanne Bechtold, University Children’s Hospital, Lindwurmstrasse 4, D-80337 Munich, Germany. E-mail: susanne.bechtold{at}med.uni-muenchen.de.

Osteopenia and growth retardation have been described in children with chronic arthritis. GH has an impact on both. In the present controlled study, we used peripheral quantitative computed tomography to evaluate forearm bone mass, density, and geometry as well as forearm muscle and fat area in 17 patients with juvenile idiopathic arthritis (JIA) receiving treatment with GH for 3.8 ± 1.1 yr compared with an untreated age- and sex-matched control group (n = 17). All patients had a mean age of 15.3 ± 2.5 yr and a mean duration of illness of 8.2 ± 4.4 yr. Height, weight, body mass index, bone parameters, and muscle area were significantly decreased in both groups compared with those in healthy age-matched children. Compared with untreated JIA patients, GH-treated JIA patients had significant higher bone mineral content as well as total cross-sectional area (CSA), cortical CSA, and muscle CSA. Fat CSA was lower in the GH-treated group. A significant difference between groups for height-corrected cortical and muscle areas was only seen in male patients. Cortical CSA relative to muscle CSA was not different between groups. These findings are compatible with an anabolic effect of GH on muscle and bone development.

This article has been cited by other articles:

				A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF]

				N J Shaw Osteoporosis in paediatrics Arch. Dis. Child. Ed. Pract., December 1, 2007; 92(6): 169 - 175. [Full Text] [PDF]

				D. Simon, A.-M. Prieur, P. Quartier, J. Charles Ruiz, and P. Czernichow Early Recombinant Human Growth Hormone Treatment in Glucocorticoid-Treated Children with Juvenile Idiopathic Arthritis: A 3-Year Randomized Study J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2567 - 2573. [Abstract] [Full Text] [PDF]

				D. S. Hardin, S. F. Kemp, and D. B. Allen Twenty Years of Recombinant Human Growth Hormone in Children: Relevance to Pediatric Care Providers Clinical Pediatrics, May 1, 2007; 46(4): 279 - 286. [Abstract] [PDF]

				G. Radetti, G. D'Addato, D. Gatti, M. Bozzola, and S. Adami Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children. Eur. J. Endocrinol., March 1, 2006; 154(3): 479 - 482. [Abstract] [Full Text] [PDF]